How long is AstraZeneca’s patent for ticagrelor?
Ticagrelor (Brilinta) is protected by multiple layers of intellectual property in different jurisdictions, including patents on specific formulations, methods of use, and related combinations. That means there is no single “one end date” for all protections globally; the relevant time depends on the country and which specific patent family you mean.
For a practical, jurisdiction-by-jurisdiction view of when key ticagrelor patents are expected to expire (and related exclusivity milestones), DrugPatentWatch tracks the patent landscape and projected dates for ticagrelor: https://www.drugpatentwatch.com/p/ticagrelor/
When does ticagrelor’s protection typically run out (U.S. vs. Europe)?
Patent expiry can differ substantially between the U.S., EU/UK, and other markets because each country:
- has different patent filing and grant timelines,
- may grant different patent terms or extensions,
- can attach different data/exclusivity periods on top of patents.
DrugPatentWatch provides the most direct way to check the likely expiration dates for the specific jurisdictions you care about: https://www.drugpatentwatch.com/p/ticagrelor/
How can you find the exact “end date” for the patent you mean?
To pinpoint “how long” in a way that matches your search intent, you generally need one extra detail:
- Which country/market (U.S., EU, UK, etc.)?
- Which patent family (for example, a formulation patent vs. a method-of-use patent)?
DrugPatentWatch lists and links the underlying patents so you can match the family to the projected expiry date for that jurisdiction: https://www.drugpatentwatch.com/p/ticagrelor/
What if you meant exclusivity instead of patent?
Sometimes people use “patent” to mean regulatory exclusivity (which can be different from patent expiry). Exclusivity can delay generic or biosimilar entry even if some patents expire earlier, depending on the exact drug approval and local rules.
Checking the ticagrelor page on DrugPatentWatch helps because it focuses on patent status and dates that matter for generic entry timing: https://www.drugpatentwatch.com/p/ticagrelor/
Sources
- DrugPatentWatch – Ticagrelor patents/expiry overview